These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26810694)

  • 1. On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.
    Lim DW; Wales PW; Turner JM; Bigam DL; Brubaker PL
    Expert Opin Ther Targets; 2016 Jul; 20(7):819-30. PubMed ID: 26810694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome.
    Lim DW; Levesque CL; Vine DF; Muto M; Koepke JR; Nation PN; Wizzard PR; Li J; Bigam DL; Brubaker PL; Turner JM; Wales PW
    Am J Physiol Gastrointest Liver Physiol; 2017 Apr; 312(4):G390-G404. PubMed ID: 28104586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects on Intestinal Adaptation Following Exogenous Glucagon-Like Peptide 2 Therapy With and Without Enteral Nutrition in Neonatal Short Bowel Syndrome [Formula: see text].
    Lim DW; Diané A; Muto M; Vine DF; Nation PN; Wizzard PR; Sigalet DL; Bigam DL; Pencharz PB; Turner JM; Wales PW
    JPEN J Parenter Enteral Nutr; 2017 Feb; 41(2):156-170. PubMed ID: 27660290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome.
    Mouksassi MS; Marier JF; Cyran J; Vinks AA
    Clin Pharmacol Ther; 2009 Dec; 86(6):667-71. PubMed ID: 19847163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of glucagon-like peptide-2 deficiency in neonatal short-bowel syndrome using neonatal piglets.
    Hua Z; Turner JM; Sigalet DL; Wizzard PR; Nation PN; Mager DR; Ball RO; Pencharz PB; Wales PW
    Pediatr Res; 2013 Jun; 73(6):742-9. PubMed ID: 23481550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teduglutide for pediatric short bowel syndrome patients.
    Rosete BE; Wendel D; Horslen SP
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):727-733. PubMed ID: 33798402
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
    Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
    Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT
    J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
    Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.
    Martin GR; Beck PL; Sigalet DL
    World J Gastroenterol; 2006 Jul; 12(26):4117-29. PubMed ID: 16830359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal adaptation following resection.
    Tappenden KA
    JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):23S-31S. PubMed ID: 24586019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
    Naimi RM; Madsen KB; Askov-Hansen C; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():47-53. PubMed ID: 23501043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome.
    Suri M; Turner JM; Sigalet DL; Wizzard PR; Nation PN; Ball RO; Pencharz PB; Brubaker PL; Wales PW
    Pediatr Res; 2014 Oct; 76(4):370-7. PubMed ID: 24995913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome.
    Pereira PM; Bines JE
    J Gastroenterol Hepatol; 2006 Jun; 21(6):932-40. PubMed ID: 16724975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to the treatments of short bowel syndrome-associated intestinal failure.
    Jeppesen PB
    Curr Opin Gastroenterol; 2014 Mar; 30(2):182-8. PubMed ID: 24406477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short bowel syndrome. GLP-2 analog teduglutide].
    Storr M
    Med Monatsschr Pharm; 2013 Sep; 36(9):343-5. PubMed ID: 24069647
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions.
    Sigalet DL
    Semin Pediatr Surg; 2018 Aug; 27(4):237-241. PubMed ID: 30342598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
    Yazbeck R
    Curr Opin Mol Ther; 2010 Dec; 12(6):798-809. PubMed ID: 21154171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model.
    Taqi E; Wallace LE; de Heuvel E; Chelikani PK; Zheng H; Berthoud HR; Holst JJ; Sigalet DL
    J Pediatr Surg; 2010 May; 45(5):987-95. PubMed ID: 20438940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.